| Literature DB >> 31861803 |
Agata Kryczyk-Poprawa1, Anna Kwiecień1, Włodzimierz Opoka1.
Abstract
Topical treatment modalities have multiple advantages starting with the convenient application and non-invasive treatment and ending with the reduction of the risk of the systemic side effects. Active pharmaceutical substances must reach the desired concentration at the target site in order to produce a particular therapeutic effect. In contrast to other dosage forms topical agents applied to the skin may also be susceptible to photodegradation after application. That is why the knowledge of the susceptibility of these topical drugs to UV irradiation, which may contribute to their degradation or changes in chemical structure, is very important. Active pharmaceutical substances used in dermatology may differ both in chemical structure and photostability. Furthermore, various factors-such as light intensity and wavelength, pH, temperature, concentration-can influence the photodegradation process, which is reflected in particular in kinetics of photodegradation of active pharmaceutical substances as well as both the quantitative and qualitative composition of by-products. The aim of this study was to conduct a systematic review of the photostability of dermatological drugs, as well as of other substances commonly applied topically. The photostability of glucocorticosteroids, retinoids, and antifungal drugs as well as non-steroidal anti-inflammatory drugs applied topically and selected UV-filters have been discussed. Furthermore, the impact of photoinstability on the effectiveness of pharmacotherapy and some photostabilization strategies have been also included.Entities:
Keywords: antifungal drugs; glucocorticosteroids; photodegradation; photostability; retinoids
Year: 2019 PMID: 31861803 PMCID: PMC7023431 DOI: 10.3390/pharmaceutics12010010
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Results by year based on the search: “photostability and drugs” and “photodegradation and drugs” (2008–2018, PubMed).
Figure 2Results based on the search for the photodegradation of the main classes of drugs reported in PubMed.
Selected classes of dermatological drugs described in terms of the photostability.
| Drug Class | Active Pharmaceutical Ingredient | Ref. |
|---|---|---|
| Glucocorticosteroids | pregna-1,4-dien-3,20-diones | [ |
| betamethasone and its esters | [ | |
| betamethasone-17 valerate | [ | |
| mometasone furoate | [ | |
| hydrocortisone 21-acetate | [ | |
| prednisolone | [ | |
| fluocinolone 16,17-acetonide | [ | |
| desonide | [ | |
| Retinoids | vitamin A | [ |
| tretinoin | [ | |
| isotretinoin | [ | |
| adapalene | [ | |
| tazarotene | [ | |
| Antifungal drugs | clotrimazole | [ |
| bifonazole | [ | |
| itraconazole | [ | |
| terbinafine | [ | |
| Non-steroidal anti-inflammatory drugs | piroxicam | [ |
| naproxen | [ | |
| diclofenac | [ | |
| ketoprofen | [ | |
| ibuprofen | [ | |
| UV filters | 4-methylbenzylidene camphor | [ |
| octyl methoxycinnamate | [ | |
| avobenzone | [ |
Photostability of retinoids reported in the literature.
| Retinoid | Presentation of Samples | Light Source | Irradiation Time/Dose | Ref. |
|---|---|---|---|---|
| Adapalene |
ethanol solution 25 mL volumetric flasks | CAMAG UV-lamp, S/N 29000, dual wavelength 254/366 nm (Switzerland) | day light, | [ |
| Adapalene with benzoyl peroxide |
adapalene 0.1% gel and 10% benzoyl peroxide lotion 10 mL plastic syringes | monochromatic sodium lamp type NA 55 W (Osram), and fluorescent lighting tubes for normal room lighting | inactinic light | [ |
| Adapalene |
gel | photostability chamber (SUN TEST XLS+, Atlas, USA). | visible light for 240 h (1.2 million lux h), | [ |
| Tazarotene |
gel 0.1% 2 g applied on 40 cm2 area on the ventral aspect of the forearms | UVB—Light Sources FS72 T12-UVB-HO bulbs | phototherapy | [ |
| Tretinoin with benzoyl peroxide |
tretinoin 0.025% gel and 10% benzoyl peroxide lotion 10 mL plastic syringes | monochromatic sodium lamp type NA 55 W (Osram), and fluorescent lighting tubes for normal room lighting | inactinic light | [ |
| Tretinoin |
lotion 0.05% ( quartz cuvette | XBO 450 W high pressure xenon lamp | distance of 28 cm | [ |
| Tretinoin |
RA-liposomes ethanol solution 1 cm quartz cuvette | light testing cabinet Suntest CPS+ (Heraeus, Milan, Italy), equipped with a Xenon lamp | light dose of 21 kJ min−1 m−2, temperature of 25 °C. | [ |
| Tretinoin |
tretinoin (0.025%) cream spread uniformly over the cover of a 35 mm tissue culture dish ethanol solution (0.025%) in Eppendorf centrifuge tubes | solar simulator, model 91293, (Oriel Corporation, Stratford, CT, USA) equipped with 1000 W Xenon lamp | distance 20 cm at 365 nm from the source, the SSL dose was 7.63 mJ/cm2/sec UVA and 0.40 mJ/cm2/sec UVB radiation, | [ |
| Isotretinoin |
13RA-liposomes ethanol solution 1 cm quartz cuvette | light testing cabinet Suntest CPS+ (Heraeus), equipped with a Xenon lamp | light dose of 21 kJ min−1 m−2, temperature of 25 °C. | [ |
| Isotretinoin |
isotretinoin (0.025%) cream spread uniformly over the cover of a 35 mm tissue culture dish ethanol solution (0.025%) in Eppendorf centrifuge tubes | solar simulator, model 91293, (Oriel Corporation) equipped with 1000 W Xenon lamp | distance 20 cm at 365 nm from the source, the SSL dose was 7.63 mJ/cm2/sec UVA and 0.40 mJ/cm2/sec UVB radiation; | [ |
| Vitamin A |
formulation spread onto an area of 10 cm2 (approximately 4 mg/cm2) of a glass plate | 96000 Oriel 150 W Xenon arc solar simulator (Oriel Corporation) | UVA/UVB irradiation (280–400 nm) UVB dose of approximately 334.8 mJ/cm2 | [ |
Strategies for improving the photostability of selected dermatological drugs.
| Active Pharmaceutical Ingredients | Photostabilizers/Excipients | Form | Percent Loss | Irradiation Dose/Time/Type/Source | Ref |
|---|---|---|---|---|---|
| Betamethasone valerate | control | cream | 49.2 ± 0.92 | UV lamp (300 W, Ultra-Vitalux Osram) | [ |
| titanium dioxide (light scattering) | 17.78 ± 1.24 | ||||
| vanillin (radical scavenger) | 27.6 ± 1.36 | ||||
| butyl hydroxytoluene (radical scavenger) | 31.0 ± 1.22 | ||||
| Betamethasone valerate | control | gel | 42.5 ± 1.64 | UV lamp | [ |
| titanium dioxide (light scattering) | 7.2 ± 0.98 | ||||
| vanillin (radical scavenger) | 13.8 ± 1.44 | ||||
| butyl hydroxytoluene (radical scavenger) | 21.9 ± 1.60 | ||||
| Betamethasone valerate cream | control (without the preservative) | topical ointment 0.1% | about 30% | UVB | [ |
| chlorocresol (excipient-preservative) | less than 10% | ||||
| Hydrocortisone 21-acetate | control (without the preservatives) | commercial formulation (cream) | 40% | UVB | [ |
| parabens: methyl- and propyl p-hydroxybenzoates (excipients—preservatives) | 20% | ||||
| Triamcinolone acetonide | control (without the preservatives) | basis cream DAC | 38% | 3 h of irradiation, | [ |
| pigmented creams (ZnO, TiO2) | 95% | ||||
| Desonide | control | hair solution (0.1%) | 61% | UVA irradiation (1350 W h/m2) | [ |
| benzophenone-3 (UV-filter, 0.3%) | 1.49% | ||||
| Vitamin A | control: 0.6% ( | topical formulation | n.d. | 30 min UVA/UVB irradiation (280–400 nm) | [ |
| octyl methoxycinnamate, avobenzone, 4-methylbenzilidene camphor | enhanced vitamin A stability | ||||
| octyl methoxycinnamate, benzophenone-3, octocrylene | enhanced vitamin A stability | ||||
| Tretinoin | solution | ethanolic solution | 92% | Sunset CPS+ (Heraeus)-xenon lamp (300–800 nm) | [ |
| liposomes | liposomes | 40% | |||
| Tretinoin | micronized tretinoin (0.05%) | gel | 9% | UVA light (315–400 nm) | [ |
| tretinoin (0.025%) | gel | 72% | |||
| Tretinoin | control: | Methanolic solution | 63% | 1 h of irradiation, | [ |
| Nanosuspension tretinoin (0.035%) | nanosuspension | 17% | |||
| Nanoemulsion tretinoin (0.035%) | nanoemulsion | 48% | |||
| Tretionoin | control: | methanolic solution | incorporation in vesicles always improved the photostability of tretinoin | UV lamp set at 366 nm (Min UVIS, Desaga, GmbH) | [ |
| niosomes tretinoin | vesicular suspensions | ||||
| Isotretinoin | control | methanol solution | 84% | natural sunlight (>20,000 Lux) | [ |
| micro-emulsion | micro-emulsion formulation | 25% | |||
| Diclofenac | control | solution | the drug appears to be more stable than the complex for T < 30 min and thereafter degrades rapidly (the complex is more stable) | 400 W mercury lamp | [ |
| 2-hydroxypropyl-β-cyclodextrin | cyclodextrin | ||||
| Piroxicam | control | piroxicam | not affected the rate of photodegradation | n.d. | [ |
| 2-hydroxypropyl-β-cyclodextrin | piroxicam-β-cyclodextrin | ||||
| Piroxicam | control | piroxicam | complex improved photostability | daylight up to 30 days | [ |
| 2-hydroxypropyl-β-cyclodextrin | piroxicam:2-hydroxypropyl-β-cyclodextrin complex | ||||
| Avobenzone | control | prepared formulation | 56%–70% (different concentration of avobenzone) | optically filtered xenon arc source | [ |
| tinosorb S | formulation with tinosorb S | 5%–15% |
n.d.—not defined.
Photosensitizing drugs used in dermatology.
| Class of Drug | Active Pharmaceutical Ingredient | Photosensitivity | Action Spectra | Ref. |
|---|---|---|---|---|
| NSAID | Ketoprofen | Phototoxic reaction Photoallergic reaction | UVA | [ |
| Naproxen | Phototoxic reaction | UVA | [ | |
| Piroxicam | Photoallergic reaction | UVA | [ | |
| Ibuprofen | Phototoxic reaction | UVA | [ | |
| Antifungal agents | Itraconazole | Phototoxic reaction | Unknown | [ |
| Voriconazole | Phototoxic reaction | UVA | [ | |
| Ketoconazole | Phototoxic reaction | Unknown | [ | |
| Griseofulvin | Phototoxic reaction | UVA | [ | |
| Retinoids | Etretinate/the major metabolite of etretinate | Phototoxic reaction | UVA/poss. UVB | [ |
| Isotretinoin | Phototoxic reaction | UVA/poss. UVB | [ | |
| Tretinoin | Phototoxic reaction | Unknown | [ | |
| UV filters | PABA derivatives | Photoallergic reaction | UVA | [ |
| Benzophenones | Photoallergic reaction | UVA | [ | |
| Isopropyl dibenzoylmethane | Photoallergic reaction | UVA | [ | |
| Cinnamates | Photoallergic reaction | UVA | [ | |
| Camphor derivatives | Photoallergic reaction | UVA | [ | |
| Avobenzone | Photoallergic reaction | UVA | [ |
poss.—possibly.